(Q38549748)

4 September 2017

1 reference

title

Chemotherapy for Nasopharyngeal Cancer: Neoadjuvant, Concomitant, and/or Adjuvant (English)

1 reference

4 September 2017

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26187796%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

author name string

Amy T Y Chang

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26187796%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

Sarah W M Lee

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26187796%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

Henry C K Sze

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26187796%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

Anne W M Lee

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26187796%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

publication date

1 September 2015

1 reference

Current Treatment Options in Oncology

4 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26187796%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

volume

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26187796%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26187796%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

page(s)

44

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26187796%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s11864-015-0361-5

14 June 2020

exact match

0 references

cites work

Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic varie

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0361-5

Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0361-5

Progress report of a randomized trial comparing long-term survival and late toxicity of concurrent chemoradiotherapy with adjuvant chemotherapy versus radiotherapy alone in patients with stage III to IVB nasopharyngeal carcinoma from endemic regions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0361-5

Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0361-5

Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0361-5

An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0361-5

Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0361-5

Preliminary results of a prospective randomized trial comparing concurrent chemoradiotherapy plus adjuvant chemotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma in endemic regions of china

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0361-5

Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0361-5

Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0361-5

Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0361-5

Concurrent chemo-radiation with or without induction gemcitabine, Carboplatin, and Paclitaxel: a randomized, phase 2/3 trial in locally advanced nasopharyngeal carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0361-5

Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiother

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0361-5

Treatment outcomes for radiotherapy alone are comparable with neoadjuvant chemotherapy followed by radiotherapy in early-stage nasopharyngeal carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0361-5

Evolution of treatment for nasopharyngeal cancer--success and setback in the intensity-modulated radiotherapy era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0361-5

Long-term outcomes of early-stage nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0361-5

Treatment outcomes after radiotherapy alone for patients with early-stage nasopharyngeal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0361-5

Treatment outcome after radiotherapy alone for patients with Stage I-II nasopharyngeal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0361-5

Staging of nasopharyngeal carcinoma--the past, the present and the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0361-5

Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0361-5

Factors contributing to the efficacy of concurrent–adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: Combined analyses of NPC-9901 and NPC-9902 Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0361-5

Improvement of survival after addition of induction chemotherapy to radiotherapy in patients with early-stage nasopharyngeal carcinoma: Subgroup analysis of two Phase III trials

21 January 2018

1 reference

12 December 2020

Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial

1 reference

12 December 2020

Long-term follow-up of a phase III study comparing radiotherapy with or without weekly oxaliplatin for locoregionally advanced nasopharyngeal carcinoma

1 reference

12 December 2020

Prognostic significance of the total dose of cisplatin administered during concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma

1 reference

12 December 2020

Concomitant radiotherapy and chemotherapy for early-stage nasopharyngeal carcinoma

1 reference

12 December 2020

Overall Survival After Concurrent Cisplatin-Radiotherapy Compared With Radiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma

1 reference

12 December 2020

Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma: a randomized phase II study conducted by the Hellenic Cooperative Oncology Grou

1 reference

12 December 2020

Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099

1 reference

12 December 2020

4th FY Khoo Memorial Lecture 2008: Nasopharyngeal Cancer Workgroup--the past, the present and the future.

1 reference

12 December 2020

Eight-signature classifier for prediction of nasopharyngeal [corrected] carcinoma survival

1 reference

12 December 2020